Modified Dakin's Solution in Reducing Radiation-Induced Dermatitis in Patients With Head and Neck Cancer Undergoing Radiation Therapy
Launched by STANFORD UNIVERSITY · Feb 17, 2015
Trial Information
Current as of May 25, 2025
Completed
Keywords
ClinConnect Summary
PRIMARY OBJECTIVES:
I. To determine the proportion of patients who develop grade 3 radiation dermatitis (as defined by the Stanford Radiation Dermatitis Scoring System) as an adverse effect of radiation therapy or chemoradiation therapy for a head and neck cancer when initiating the use of prophylactic hypochlorite (HOCl) (modified Dakin's solution) at the start of therapy (experimental arm) compared to placebo (control arm).
OUTLINE: Patients are randomized to 1 of 2 arms.
ARM I (EXPERIMENTAL): Participants apply modified Dakin's solution (0.005% to 0.010%) topically to the skin of the ...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Head and neck cancer who plan to undergo radiation therapy to the head and neck region
- • At least 18 years of age
- • Able to understand and the willingness to sign a written informed consent document.
- Exclusion Criteria:
- • Prior radiation therapy to the head and neck region or prior chemotherapy for head and neck cancer (induction chemotherapy NOT excluded)
- • The physician-approved radiation treatment plan indicates a maximum prescription dose of less than 45 Gy
- • Scleroderma or discoid lupus
About Stanford University
Stanford University is a prestigious academic institution renowned for its cutting-edge research and innovation in healthcare and medicine. As a clinical trial sponsor, Stanford leverages its extensive resources, including a collaborative network of world-class researchers and state-of-the-art facilities, to advance medical knowledge and improve patient care. The university is committed to conducting rigorous, ethical research that adheres to the highest standards of scientific integrity, fostering an environment where groundbreaking discoveries can translate into effective clinical applications. Through its clinical trials, Stanford aims to address critical health challenges and contribute to the development of novel therapies and treatment strategies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Stanford, California, United States
San Jose, California, United States
Patients applied
Trial Officials
Beth Beadle
Principal Investigator
Stanford University Hospitals and Clinics
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials